See more : ShockWave Medical, Inc. (SWAV) Income Statement Analysis – Financial Results
Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AKM CREATIONS LIMITED (AKM.BO) Income Statement Analysis – Financial Results
- Koramco Energy Plus Reit (357120.KS) Income Statement Analysis – Financial Results
- PT Jakarta Setiabudi Internasional Tbk (JSPT.JK) Income Statement Analysis – Financial Results
- AMB Financial Corp. (AMFC) Income Statement Analysis – Financial Results
- Barbeque Nation Hospitality Ltd. (BARBEQUE.NS) Income Statement Analysis – Financial Results
Fennec Pharmaceuticals Inc. (FENC)
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.25M | 1.54M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.68 |
| Cost of Revenue | 1.26M | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -55.23K | 0.00 |
| Gross Profit | 19.99M | 1.45M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.23K | 0.68 |
| Gross Profit Ratio | 94.08% | 94.40% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,359,700.00% | 100.00% |
| Research & Development | 56.00K | 3.53M | 4.98M | 5.11M | 5.61M | 5.01M | 1.94M | 472.00K | 256.00K | 357.00K | 597.00K | 2.08M | 1.49M | 708.00K | 2.11M | 10.37M | 10.91M | 14.00M | 12.44M | 3.59M | 3.55M | 3.13M | 1.91M | 939.36K |
| General & Administrative | 20.59M | 17.72M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.12M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 1.94M | 3.90M | 1.21M | 3.52M | 3.28M | 2.88M | 3.18M | 3.49M | 1.78M | 907.40K | 738.72K | 614.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.00K | -17.00K | 6.00K | -8.00K | -14.00K | 0.00 | 0.00 | -3.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18M | 2.72M | 2.34M | 1.42M | 0.00 | 55.23K | 52.01K |
| Operating Expenses | 32.76M | 24.04M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.70M | 1.61M |
| Cost & Expenses | 34.06M | 24.12M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.65M | 1.61M |
| Interest Income | 441.00K | 195.00K | 54.00K | 87.00K | 322.32K | 0.00 | 0.00 | 0.00 | 3.00K | 2.00K | 2.00K | 25.00K | 43.00K | 32.00K | 47.00K | 286.00K | 833.00K | 0.00 | 361.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.39M | 978.00K | 126.00K | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | 11.00K | -444.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.00K | 149.00K | 17.22M | 402.00K | 13.01M | 10.41M | 6.95M | 2.87M | -1.23M | -699.00K | -1.00K | 20.00K | 43.00K | 3.25M | 615.00K | 164.00K | 192.00K | 2.43M | 3.06M | 2.52M | 1.61M | 123.76K | 55.23K | 52.01K |
| EBITDA | -12.36M | -22.59M | -123.00K | -17.89M | 234.00K | 521.00K | -95.00K | 82.00K | -1.89M | -2.88M | 1.79M | -5.18M | 4.55M | -4.60M | -2.60M | -13.89M | -14.19M | -17.91M | -19.27M | -12.56M | -5.22M | -4.24M | -2.79M | -2.59M |
| EBITDA Ratio | -58.18% | -1,468.60% | 0.00% | -10,579.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -421,928,118.14% | -231,162,432.56% |
| Operating Income | -12.77M | -22.59M | -17.22M | -17.89M | -13.01M | -10.41M | -6.95M | -2.87M | -1.89M | -2.88M | -1.93M | -3.62M | -3.44M | -4.60M | -3.22M | -13.89M | -14.19M | -19.06M | -18.35M | -9.42M | -6.74M | -4.04M | -2.65M | -1.61M |
| Operating Income Ratio | -60.09% | -1,471.60% | 0.00% | -10,520.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -400,900,112.25% | -237,629,943.17% |
| Total Other Income/Expenses | -3.27M | -1.13M | -123.00K | -224.00K | 234.00K | 521.00K | -95.00K | 82.00K | 1.28M | 701.00K | 3.78M | -1.54M | 8.12M | -3.51M | 204.00K | 0.00 | 905.96K | -1.54M | -3.99M | -227.00K | 79.44K | 321.36K | 194.17K | 8.31K |
| Income Before Tax | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -20.64M | -21.54M | -9.59M | -6.67M | -3.72M | -2.45M | -1.60M |
| Income Before Tax Ratio | -75.50% | -1,544.89% | 0.00% | -10,652.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| Income Tax Expense | 0.00 | 1.13M | 110.00K | -187.00K | -315.00K | -348.00K | -47.00K | -8.00K | -3.00K | -2.00K | -2.00K | -25.00K | -43.00K | 7.82M | 3.01M | 13.60M | 13.36M | -1.54M | -2.29M | -854.68K | -518.20K | 3.72M | 2.45M | 1.60M |
| Net Income | -16.05M | -24.84M | -17.46M | -17.92M | -12.46M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Net Income Ratio | -75.50% | -1,618.18% | 0.00% | -10,542.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| EPS | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.19 | -0.63 | 0.59 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -20.12 | -2.98 |
| EPS Diluted | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.62 | 0.58 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -4.04 | -2.98 |
| Weighted Avg Shares Out | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 18.94M | 14.99M | 12.68M | 10.83M | 9.87M | 9.72M | 8.20M | 7.99M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 122.02K | 536.64K |
| Weighted Avg Shares Out (Dil) | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 19.02M | 15.01M | 12.77M | 10.83M | 9.87M | 10.57M | 8.39M | 8.02M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 607.09K | 536.64K |
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before...
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors
Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?
The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growth in the US, and completion of a Japanese bridging...
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE...
Source: https://incomestatements.info
Category: Stock Reports